MORBELLI S.

No description

Alzheimer's disease (AD) is a heterogeneous illness including "atypical" clinical presentations dominated by visual, aphasic, "frontal" (behavioral), or apraxic symptoms. Initial description of atypical phenotypes of AD was based on clinicopathologic studies, but there is a growing body of evidence coming from in vivo molecular biomarkers...

: This series of eight papers (five original articles, two reviews and one meta-analysis) is presented by international leaders covering various aspects of lung cancer management, starting with diagnostic imaging and analyzing the novel perspectives of therapy [...].

We describe the case of an 82-year-old man who underwent 68 Ga-prostate-specific membrane antigen-11 (68 Ga-PSMA-11) positron emission tomography/computed tomography (PET/CT) for the restaging of prostate carcinoma. 68 Ga-PSMA-11 PET/CT unexpectedly showed increased tracer uptake homogenously involving the axial and appendicular bone marrow and...

Neuroendocrine differentiation (NED) of prostate cancer represents an acknowledged predictor of resistant and more aggressive disease. NED can be functionally exploited in vivo using PET/CT imaging with somatostatin analogs radiolabeled with 68Ga. Many previous reports have shown that 18F-FDG PET/CT should also be used in cases such as guiding...

Metabolic connectivity analysis of resting 18F-FDG PET is based on the assumption that brain regions whose metabolism is significantly correlated at rest are functionally associated and that the strength of the association is proportional to the magnitude of the correlation coefficient. Therefore, this method could be used to evaluate...

2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) is a promising tool to support the evaluation of response to either target therapies or immunotherapy with immune checkpoint inhibitors both in clinical trials and, in selected patients, at the single patient's level. The present review aims to discuss available evidence related to the use of [18F]FDG...

Over the past two decades, one of the major breakthroughs for the approach to neurological diseases both in the clinical and research settings has been represented by the validation of diagnostic biomarkers able to demonstrate the presence of pathological mechanisms, alteration in neurotransmission as well as to predict disease progression [1,...

Movement disorders are a group of neurological diseases (recognizing neurodegenerative and non-neurodegenerative etiologies) whose primary symptomatology is related to the lack of movement or, conversely, to an excessive and/or involuntary movement. Among them, neurodegenerative parkinsonian syndromes include Parkinson's Disease, Dementia with...

No description

No description

No description

No description

Purpose: The present review aims to discuss indications for the use of [18F]-FDG PET in patients with APS associated with dementia as emerged in the EANM/EAN joint recommendations for its use in dementia. New lines of evidence emerged after the EANM/EAN consensus have here been systematically reviewed. Methods: We searched in the databases...

No description

No description